Combinations with other PD-1/PD-L1 and CTLA-4 inhibitors have also been tested; the MYSTIC trial was a phase 3 randomized, open-label, trial comparing the anti-PDL1 antibody durvalumab (D) as monotherapy or combined with the anti-CTLA-4 antibody tremelimumab (T) with platinum-based chemotherapy as first-line treatment in patients with metastatic or locally advanced (stage IV) NSCLC. The gene discussed is CTLA4; the disease is non-small cell lung carcinoma.